WHO investigating links between cough syrup deaths

 The World Health Organization (WHO) is investigating whether there is any connection between manufacturers whose contaminated cough syrups it has linked to the deaths of more than 300 children in three countries, a person familiar with the matter told Reuters.

Citing “unacceptable levels” of toxins in the products, the WHO is seeking more information about the specific raw materials used by six manufacturers in India and Indonesia to produce medicines linked to the recent deaths, as well as whether the companies obtained them from some of the same suppliers, the person said. The WHO has not named any suppliers.

The WHO also is considering whether to advise families globally to reassess the use of cough syrups for children in general while questions over the safety of some of these products are unresolved, the person said. WHO experts are evaluating the evidence for whether, or when, such products are medically necessary for children, the person said.

The deaths of children from acute kidney injury began in July 2022 in Gambia, followed by cases in Indonesia and Uzbekistan. The WHO has said the deaths are linked to over-the-counter cough syrups the children took for common illnesses and which contained a known toxin, either diethylene glycol or ethylene glycol.

To date, the WHO has identified six drugmakers in India and Indonesia who produced the syrups. These manufacturers have either declined to comment on the investigation or denied using contaminated materials that contributed to any deaths. Reuters has no evidence of wrongdoing by the companies the WHO has named.

Read more: Rs.240,566,109 utilized to cater catastrophic health expenditures of deserving patients during

“This is of the highest priority for us, to see no more child deaths from something that is so preventable,” WHO spokesperson Margaret Harris said, without commenting further on the details of the organisation’s work.

The United Nations health agency said on Monday it had widened its investigation into potential diethylene glycol and ethylene glycol contamination in cough syrups to four additional countries where the same products may have been on sale: Cambodia, the Philippines, East Timor and Senegal. It called on other governments and the global pharmaceutical industry to launch urgent checks to root out substandard medicines and improve regulation.

The WHO is expected to comment further on the cough syrup situation during a news conference later on Tuesday.

The WHO has already issued specific alerts for cough syrups made by two Indian manufacturers, Maiden Pharmaceuticals and Marion Biotech, in October 2022 and earlier this month. It said their syrups were linked to deaths in Gambia and Uzbekistan respectively, and the alerts asked people to stop using them.

Maiden and Marion’s manufacturing plants have both been shuttered. Maiden is now seeking to reopen after the Indian government said in December that its testing had found no problems with Maiden’s products.

Maiden has repeatedly told Reuters, including in December, that it did nothing wrong and Managing Director Naresh Kumar Goyal said on Tuesday he had no comment on WHO investigating possible connections between the companies under scrutiny.

Marion’s office phone went unanswered on Tuesday and the company did not immediately respond to an email seeking comment. Earlier this month, it told the government of Uttar Pradesh, where it is located near New Delhi, that it was being blamed for the deaths in Uzbekistan “to malign the image of India and the company”.

Do you want to read authentic news from Pakistan & across the world? So download MM News App Now !
Comments: 0

Your email address will not be published. Required fields are marked with *